ВУЗ: Не указан
Категория: Не указан
Дисциплина: Не указана
Добавлен: 17.03.2025
Просмотров: 2227
Скачиваний: 3
186 |
Chapter 10 |
33.S. Stamatovic, P. Shakui, R. Keep, B. Moore, S. Kunkel, N. Van Rooijen and A. Andjelkovic, J. Cereb. Blood Flow Metab., 2005, 25, 593.
34.M. Fiala, Q. Liu, J. Sayre, V. Pop, V. Brahmandam, M. Graves and
H.Vinters, Eur. J. Clin. Invest., 2002, 32, 360.
35.A. Jana and K. Pahan, J. Biol. Chem., 2004, 279, 51451.
36.G. Arboleda, T. Huang, C. Waters, A. Verkhratsky, P. Fernyhough and
R.Gibson, Eur. J. Neurosci., 2007, 25, 3030.
37.C. Gong, F. Liu, I. Grundke-Iqbal and K. Iqbal, J. Alzheimer’s Dis., 2006, 9, 1.
38.S. Hoyer, Eur. J. Pharmacol., 2004, 490, 115.
39.I. Matia and V. Di Marzo, Trends Endocrinol. Metab., 2006, 18, 27.
40.D. Centonze, A. Finazzi-Agro, G. Bernardi and M. Maccarrone, Trends Pharmacol. Sci., 2007, 28, 180.
41.A. Hartz, D. Miller and B. Bauer, Mol. Pharmacol., 2010, 77, 715.
42.M. Fiala, Q. Liu, J. Sayre, V. Pop, V. Brahmandam, V. Graves and
M.Vinters, Eur. J. Clin. Invest., 2002, 32, 360.
43.S. Stamatovic, P. Shakui, R. Keep, B. Moore, S. Kunkel, N. Van Rooijen and A. Andjelkovic, J. Cereb. Blood Flow Metab., 2005, 25, 593.
44.A. Reijerkerk, G. Kooij, S. van der Pol, T. Leyen, B. van Het Hof,
P.Couraud, D. Vivien, C. Dijkstra and H. de Vries, J. Immunol., 2008, 181, 3567.
45.J. Sethi and A. Vidal-Puig, Trends Mol. Med., 2005, 11, 344.
46.J. Revollo, A. Grimm and S. Imai, Curr. Opinion Gastroenterol., 2007, 23, 164.
47.C. Haskell, M. Wong, A. Williams and L. Lee, Med. Ped. Oncol., 1996, 27, 165.
48.F. Berger, M. Ramirez-Hernandez and M. Ziegler, Trends Biochem. Sci., 2004, 29, 111.
49.J. Beckman, D. Parks, J. Pearson, P. Marshall and B. Freeman, Free Radic. Biol. Med., 1989, 6, 607.
50.E. Ellis, D. Guberski, B. Hutson and M. Grant, Nitric Oxide Biol. Chem., 2002, 6, 295.
51.F. Martin-Romero, E. Garcia-Martin and C. Gutierrez-Merino, J. Neurochem., 2002, 82, 705.
52.T. Peng, X. Lu and Q. Feng, Circ., 2005, 111, 1637.
53.S. Malik, F. Vaillant and A. Lawen, Biofactors, 2004, 20, 189.
54.M. Lupke, J. Rollwitz and M. Simko, Free Radic. Res., 2004, 38, 985.
55.D. Morre, F. Guo and D. Morre, Mol. Cell. Biochem., 2003, 254, 101.
56.M. Berridge and A. Tan, Antiox. Redox Signaling, 2000, 2, 277.
57.H. Sumimoto, K. Miyano and R. Takeya, Biochem. Biophys. Res. Commun., 2005, 338, 677.
58.C. Markert, D. Morre and D. Morre, Biofactors, 2004, 20, 207.
59.J. Adams and L. Klaidman, Lett. Drug Design Disc., 2007, 4, 44.
60.P. Belenky, K. Bogan and C. Brenner, Trends Biochem. Sci., 2006, 32, 12.
61.C. Snell, P. Snell and C. Richards, J. Neurochem., 1984, 43, 1610.
62.T. Dahl, A. Yndestad, M. Skjelland, E. Oje, A. Dahl, A. Michelsen,
J.Damas, S. Tunheim, T. Ueland, C. Smith, B. Bendz, S. Tonstad,
L.Gullestad, S. Froland, K. Krohg-Sorensen, D. Russell, P. Aukrust and
B.Halvorsen, Circ., 2007, 115, 972.
DNA, Nuclear Cell Signaling and Neurodegeneration |
187 |
63.A. Moschen, A. Kaser, B. Enrich, B. Mosheimer, M. Theurl, H. Niederegger and H. Tilg, J. Immunol., 2007, 178, 1748.
64.F. Lago, C. Dieguez J. Gomez-Reino and O. Gualillo, Cytokine Growth Factor Rev., 2007, 18, 313.
65.S. Ritchie and J. Connell, Nutr. Metab. Cardiovasc. Dis., 2007, 17, 319.
66.Y. Matsuzawa, FEBS Lett., 2006, 580, 2917.
67.B. Altura, A. Gebrewold, Z. Tao and B. Altura, Brain Res. Bull., 2002, 58, 271.
68.F. Wu and J. Wilson, Cardiovasc. Res., 2009, 81, 38.
69.L. Klaidman, M. Morales, S. Kem, J. Yang, M. Chang and J. Adams, Pharmacol., 2003, 69, 150.
70.J. Adams, L. Klaidman, Y. Huang, J. Cheng, Z. Wang, M. Nguyen,
B.Knusel and A. Kuda, Mol. Chem. Neuropath., 1994, 22, 123.
71.M. Meisterernst, G. Stelzer and R. Roeder, Proc. Natl. Acad. Sci. U.S.A., 1997, 94, 2261.
72.F. Althaus and C. Richter, in ADP-Ribosylation of Proteins. Enzymology and Biological Significance, Springer-Verlag, Berlin, 1987, p. 45.
73.S. Oei, J. Griesenbeck, M. Ziegler and M. Schweiger, Biochem., 1998, 37, 1465.
74.M. Malangua, J. Pleschke, H. Kleczkowska and F. Althaus, J. Biol. Chem., 1998, 17, 11839.
75.C. Cairns and R. White, EMBO. J., 1998, 17, 3112.
76.M. Jacobson and E. Jacobson, Trends Biochem. Sci., 1999, 24, 415.
77.L. Klaidman, S. Mukherjee and J. Adams, Biochim. Biophys. Acta, 2001, 1525, 136.
78.C. Szabo, L. Lim, S. Cuzzocrea, S. Getting, B. Zingarelli, R. Flower,
A.Salzman and M. Perretti, J. Exp. Med., 1997, 186, 1041.
79.W. Jonas, C. Rapoza and W. Blair, Inflamm. Res., 1996, 45, 330.
80.C. Szabo, Eur. J. Pharmacol., 1998, 350, 1.
81.M. Fujimura, T. Tominaga and T. Yoshimoto, Neurosci. Lett., 1997, 228, 107.
82.J. Adams, L. Williams, S. Mukherjee, L. Klaidman, G. Inouye, V. Cummins and M. Morales, in Free Radicals in Brain Pathophysiology, ed. G. Poli,
E.Cadenas and L. Packer, Marcel Dekker, Inc., New York, 2000, p. 55.
83.J. Yang, L. Klaidman, M. Chang, S. Kem, T. Sugawara, P. Chan and
J.Adams, Pharmacol. Biochem. Behav., 2002, 73, 901.
84.J. Adams, B. Wang, L. Klaidman, C. LeBel, I. Odunze and D. Shah, Free Radic. Biol. Med., 1993, 15, 195.
85.S. Mukherjee, R. Yasharel, L. Klaidman, T. Hutchin and J. Adams, Brain Res. Bull., 1995, 38, 595.
86.S. Mukherjee, M. Sonee and J. Adams, Lett. Drug Design Disc., 2005, 2, 551.
87.K. Feeney, C. Wasson and J. Parish, Biochem. J., 2010, 428, 147.
88.D. Jung, D. Jin, S. Hong, J. Kim, J. Shin, D. Kim, B. Cho, Y. Hwang,
J.Kang and W. Lee, J. Biol. Chem., 2010, 285, 7995.
89.A. Vasilopoulos, C. Deng and T. Chavakis, Int. J. Biochem. Cell Biol., 2010, 42, 193.
CHAPTER 11
G Protein-Coupled Receptors: Conformational ‘‘Gatekeepers’’ of Transmembrane Signal Transduction and Diversification
RAVINDER ABROL* AND WILLIAM A.
GODDARD III, FRSC*
Materials and Process Simulation Center (MC 139-74), California Institute of Technology, 1200 E California Blvd, Pasadena, CA 91125, USA
11.1 Introduction
Cells are the fundamental units of all known life forms. This central role requires the cells to sense and interact with their environment or other cells and produce a physiological response vital to the proper functioning of the cell. Cellular signaling machinery is comprised of di erent proteins that enable and drive the amazing plethora of functions necessary for growth, survival and eventual death at the cellular level and in turn at the organism level (for multi-cellular life).
Cells need to process signals produced both inside and outside the cell. The extracellular signals can originate from other cells in the same organism (e.g. adrenaline), other organisms (e.g. pheromones) or the environment (e.g. photons, tastants, etc.). Cellular signaling proteins have evolved to sense this diverse set of signals either via direct contact with the signals
RSC Drug Discovery Series No. 10 Extracellular and Intracellular Signaling
Edited by James D. Adams, Jr. and Keith K. Parker r Royal Society of Chemistry 2011
Published by the Royal Society of Chemistry, www.rsc.org
188
G Protein-Coupled Receptors: Conformational ‘‘Gatekeepers’’ |
189 |
(e.g. binding to the signaling molecule) or via binding to other proteins that are in direct contact with the signals. Di erent cells are also programmed to sense di erent signals depending on the proteins expressed in their plasma membrane. These membrane proteins not only enable signal transmission, but also signal modulation and diversification by undergoing conformational changes and/or through the specificity of protein-protein interactions.
Transmembrane (TM) signal transduction by membrane proteins is the dominant component of cellular signaling, as it enables a cell to convert an extracellular signal into one or more intracellular signals or responses. There are three main classes of membrane proteins that enable TM signal transduction: ion-channel receptors, enzyme-linked receptors and G protein-coupled receptors (GPCRs), with GPCRs playing the most prominent role.
In this chapter, we will focus on GPCRs and use current structural insights from experiments and computational predictions to describe the spectacular role played by conformationally malleable GPCRs in sensing extracellular signals, which cover a broad spectrum from photons (for vision), chemosensory ligands (e.g. for taste and smell) and neurotransmitters/hormones (e.g. dopamine, serotonin, adrenaline, acetylcholine) to peptides (e.g. cytokines) and larger proteins. Being receptors for neurotransmitters, hormones and cytokines, GPCRs have been implicated in a majority of disease processes, which has made them a very attractive target for therapeutic applications, as blocking or activating these receptors by antagonists or agonists respectively blocks or activates a whole cascade of signaling events. However, di erent subtypes of a GPCR (capable of sensing the same agonist) might induce a di erent or even opposite response to the signal depending on the cell type and the location in the organism. This is one of the many reasons that most drugs have side-e ects and the lack of complete knowledge about the signaling pathways being manipulated by drugs makes it di cult to ascertain whether some of the side-e ects are caused by o -target proteins (other proteins or other subtypes of the target protein) or by the target protein itself. Designing GPCR drugs with no or minimal side-e ects is one of the biggest challenges in the rational design of GPCR targeting therapeutics.
This chapter contains a brief section on cellular signaling to provide some background and context for GPCR-mediated signal transduction followed by a detailed section on GPCRs, which is divided into subsections on their structure, signal-induced conformation driven signal transduction (amplification and diversification), biased signaling induced by extracellular ligands and challenges in rational design of GPCR targeting drugs. The focus of the chapter is the processing and modulation of extracellular signals by GPCRs, so discussion on intracellular signaling pathways will be limited and will only focus on their direct connection to GPCR activation. The chapter concludes with a brief section on the discoveries and challenges that lie ahead for GPCR-mediated signaling.